Immunotherapies Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapies stocks.

Immunotherapies Stocks Recent News

Date Stock Title
May 10 ACLX Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
May 10 GNLX Genelux GAAP EPS of -$0.29 misses by $0.06
May 10 ACLX Arcellx GAAP EPS of -$0.14, revenue of $39.3M
May 10 ACLX Kite and Arcellx prepare to launch Phase III multiple myeloma trial
May 10 GRTS Gritstone bio Inc. (GRTS) Q1 2024 Earnings Call Transcript
May 9 PDSB PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
May 9 ACLX Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset
May 9 ACLX Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
May 9 GRTS Gritstone bio GAAP EPS of -$0.34 misses by $0.02, revenue of $1.74M misses by $1.11M
May 9 GNLX Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
May 9 ACLX Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 9 GRTS Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 9 ACLX Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 9 ACLX Arcellx Provides First Quarter 2024 Financial Results
May 9 CGON CG Oncology, Inc. reports Q1 results
May 9 PDSB PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
May 9 CGON CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
May 9 PYXS Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
May 8 GRTS Gritstone bio Q1 2024 Earnings Preview
May 7 ACLX Arcellx to Participate in Two Upcoming Investor Conferences
Immunotherapies

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags